Cancer is one of the main reasons of death in the most countries and in Iran. Immunotherapy
quickly became one of the best methods of cancer treatment, along with chemotherapy and …

Since the discovery of apoptosis as a form of programmed cell death, targeting the apoptosis
pathway to induce cancer cell death has been a high-priority goal for cancer therapy. After …

Immunotoxins are antibody-toxin bifunctional molecules that rely on intracellular toxin action
to kill target cells. Target specificity is determined via the binding attributes of the chosen …

Purpose Maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were
assessed in this phase 1 study of PNT2258, a BCL-2-targeted liposomal formulation of a 24 …

Anthrax toxin is a potent tripartite protein toxin from Bacillus anthracis. It is one of the two
virulence factors and causes the disease anthrax. The receptor-binding component of the …

Recombinant immunotoxins (RITs) are proteins that contain a toxin fused to an antibody or
small molecules and are constructed by the genetic engineering technique. RITs can bind to …

Immunotoxins are a class of targeted cancer therapeutics in which a toxin such as
Pseudomonas exotoxin A (PE) is linked to an antibody or cytokine to direct the toxin to a …

ABSTRACT Myeloid cell leukemia 1 (MCL-1) is a prosurvival BCL-2 protein family member
highly expressed in hematopoietic stem cells (HSCs) and regulated by growth factor signals …

Small cell lung cancer (SCLC) accounts for 15% of lung cancer cases and is associated with
a dismal prognosis. Standard therapeutic regimens have been improved over the past …

BCL-xL and BCL-2 are validated therapeutic targets in small-cell lung cancer (SCLC).
Targeting these proteins with navitoclax (formerly ABT263, a dual BCL-xL/2 inhibitor) …